Skip to content

Federal Contractor Profile

Resilience Government Services, INC.

$292M obligated·18 awards·2 agencies·5 NAICS

Federal Contracts

Showing award actions 1–50 of 81 funded award actions, most recent first.

Contracts with positive obligations
18
Funded award actions shown
81
Obligations shown
$292M
Awarding agencies
2

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of August 20, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Sep 23, 2025Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$1.6M
Sep 10, 2024Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$4.5M
Jul 31, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$750K
Jun 25, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023F00001541711DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT$314K
May 23, 2024Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.0M
Mar 28, 2024Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$3.0M
Mar 26, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$473K
Feb 21, 2024Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.1M
Nov 2, 2023Department of DefenseW6QK ACC-APGW911SR22F0073541715DS PROCESS CHARACTERIZATION$1000K
Nov 1, 2023Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$2.2M
Oct 30, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$2.8M
Sep 25, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$489K
Sep 12, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$3.8M
Aug 25, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023F00001541711DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT$485K
Aug 17, 2023Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$135K
Aug 8, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$4.8M
Aug 3, 2023Department of DefenseW6QK ACC-APGW911SR22F0073541715DS PROCESS CHARACTERIZATION$1.1M
Aug 3, 2023Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$400K
Jun 29, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$4.4M
Jun 23, 2023Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$681K
Apr 12, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.8M
Mar 9, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$12M
Mar 8, 2023Department of DefenseW6QK ACC-APGW911SR23F0057541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$4.4M
Mar 7, 2023Department of DefenseW6QK ACC-APGW911SR22F0073541715DS PROCESS CHARACTERIZATION$2.0M
Feb 17, 2023Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$5.6M
Feb 13, 2023Department of DefenseW6QK ACC-APGW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$81K
Feb 9, 2023Department of DefenseW6QK ACC-APGW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$123K
Nov 30, 2022Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$3.0M
Aug 1, 2022Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$2.3M
Jun 30, 2022Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$21M
Jun 16, 2022Department of DefenseW6QK ACC-APGW911SR22F0073541715DS PROCESS CHARACTERIZATION$2.4M
Apr 30, 2022Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$22M
Feb 22, 2022Department of DefenseW6QK ACC-APGW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.8M
Jan 5, 2022Department of DefenseW6QK ACC-APGW911SR22F0014541715CLINICAL DEVELOPMENT PHASE 2 STUDY$19M
Dec 18, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$272K
Jun 24, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$612K
Feb 19, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$3.6M
Feb 17, 2021Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.9M
Dec 16, 2020Department of DefenseW6QK ACC-APG NATICKW911QY20C0101325412FILL AND FINISH CAPACITY$39M
Sep 7, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.1M
Aug 17, 2020Department of DefenseW6QK ACC-APG NATICKW911QY20C0101325412FILL AND FINISH CAPACITY$53M
Aug 4, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.2M
Jun 10, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$800K
May 14, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$680K
Apr 15, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$485K
Mar 4, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00057541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$1.8M
Feb 25, 2020Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.0M
Feb 18, 2020Department of DefenseW6QK ACC-APG NATICKW911QY19C0049541714PMR AND PMC$125K
Dec 31, 2019Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$2.4M
Dec 13, 2019Department of DefenseW6QK ACC-APG NATICKW911QY13C0010325412MEDICAL COUNTERMEASURES ADVANCED DEVELOPMENT AND MANUFACTURING (MCM ADM) CAPABILITY$1.3M

Get Alerted Before Resilience Government Services, INC.'s Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free